We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
24 Jan 20
TAZVERIK is indicated for the treatment of metastatic epithelioid sarcoma in patients who are not eligible for complete…
21 Jan 20
Mayzent selectively binds to S1P1 and S1P5 receptors to prevent lymphocytes from leaving the lymph nodes and entering…
20 Jan 20
BBT-176 has demonstrated strong anti-tumour efficacy, and enhanced efficacy when used along with anti-EGFR antibodies in the pre-clinical…
17 Jan 20
The FDA approval is based on the results of SUSTAIN 6 cardiovascular outcomes trial (CVOT) which showed positive…
16 Jan 20
Dovato is a once-daily, single-pill, 2-drug regimen that combines integrase inhibitor (INI) dolutegravir, and the nucleoside reverse transcriptase…
16 Jan 20
Janssen has secured the European Commission approval of SPRAVATO nasal spray for treatment-resistant major depressive disorder (TRD), in…
13 Jan 20
Fostemsavir was submitted for the US FDA new drug application (NDA), and was granted FDA fast track and…
10 Jan 20
AYVAKIT marks the first precision therapy to be approved by the FDA to treat a genomically defined population…
09 Jan 20
FDA has approved KEYTRUDA based on data from KEYNOTE-057, a multicentre, open-label, single-arm trial, involving 96 patients
07 Jan 20
In the Phase III DAPA-HF trial, Farxiga has reduced the incidence of the composite outcome of CV death…